Sepsis Pipeline Review H2 2016
Global Markets Direct's, Sepsis - Pipeline Review, H2 2016', provides an overview of the
Sepsis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for
Sepsis , complete with analysis by stage of development, drug target, mechanism of action
(MoA), route of administration (RoA) and molecule type. The report also covers the descriptive
pharmacological action of the therapeutics, its complete research and development history and
latest news and press releases. Additionally, the report provides an overview of key players
involved in therapeutic development for Sepsis and features dormant and discontinued
projects.
The report helps in identifying and tracking emerging players in the market and their portfolios,
enhances decision making capabilities and helps to create effective counter strategies to gain
competitive advantage.
Complete report on Sepsis - Pipeline Review, H2 2016 addition with 77 market data tables and
15 figures, spread across 240 pages http://www.rnrmarketresearch.com/sepsis-pipelinereview-h2-2016-market-report.html
This report features investigational drugs from across globe covering over 20 therapy areas and
nearly 3,000 indications. The report is built using data and information sourced from Global
Markets Direct's proprietary databases, company/university websites, clinical trial registries,
conferences, SEC filings, investor presentations and featured press releases from
company/university sites and industry-specific third party sources. Drug profiles featured in
the report undergoes periodic review following a stringent set of processes to ensure that all
the profiles are updated with the latest set of information. Additionally, various dynamic
tracking processes ensure that the most recent developments are captured on a real time basis
Drugs Profile Discussed in this Research:
3K3A-APC, 7-H9 AB-022, AcPepA , adrecizumab,ALT-836,Aspidasept, Atu-111, BI-113823, Biologic
to Inhibit PD-L1 for Immunology, BMS-936559, ceftaroline fosamil, Drug for Sepsis and Septic Shock,
Escherichia coli vaccine, ImmStem,ImmuneSafe,Klebsiella pneumoniae vaccine,levosimendan,
meropenem,Metablok,Micselon, Motrem RBM-005,Slit2N,Disease and Toxicology,tosatoxumab, TRX306 Synthetic Peptides for Immunology and Infectious Diseases, Small Molecule for Immunology,
CNS, Cardiovascular and Infectious Disease
Companies Discussed/Mentioned in this Research:
Adrenomed , Altor BioScience Corporation, Arch Biopartners, Asahi Kasei Pharma Corp, Astellas
Pharma, Batu Biologics, Biomedica Management Corporation, Boehringer Ingelheim, Cell2B S.A.,
Chiesi Farmaceutici, Chiome Bioscience, Cilian AG, Cognosci, Cytheris SA, Endacea, Evec, Huons ,
InflaRx , Inotrem , OncoImmune, Opsona Therapeutics Limited, Orion Oyj, Ra Pharmaceuticals,v,
Shionogi & Co, Silence Therapeutics Syntiron , TaiRx, Therakind Limited, Therashock TiGenix ,
XImmune
Inquire before buying for this http://www.rnrmarketresearch.com/contacts/inquire-beforebuying?rname=662424(This is a premium report price at US$2000 for a single user PDF
license).